CEACAM5 and lung adenocarcinoma: Finally, we used EGFR-mutant lung adenocarcinoma cells to monitor the change of CEA heterogeneity after EGFR-TKI treatment and its association with dissemination and chemoresistant properties of lung cancer cells.